

Sexually Transmitted Disease Surveillance 2007

**Division of STD Prevention
December 2008**

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of STD Prevention
Atlanta, Georgia 30333

Centers for Disease Control and
Prevention.....Julie Louise Gerberding, M.D., M.P.H.
Director

Coordinating Center for
Infectious DiseasesMitchell L. Cohen, M.D.
Director

National Center for HIV/AIDS, Viral Hepatitis, STD,
and TB Prevention.....Kevin Fenton, M.D., Ph.D.
Director

Division of STD PreventionJohn M. Douglas, Jr., M.D.
Director

Epidemiology and Surveillance
BranchStuart M. Berman, M.D., Sc.M.
Chief

Surveillance and Special Studies
TeamHillard S. Weinstock, M.D., M.P.H.
Lead

Statistics and Data Management
BranchSamuel L. Groseclose, D.V.M., M.P.H.
Chief

Delicia Carey, Ph.D.
Team Lead

Copyright Information

All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.

Suggested Citation

Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance, 2007*. Atlanta, GA: U.S. Department of Health and Human Services; December 2008.

Printed copies and the on-line version of this report can be obtained at the following web site:
<http://www.cdc.gov/std/pubs/>

Selected STD Surveillance and Prevention References and Websites

Supplemental STD Surveillance Reports – 2007

- 2007 Chlamydia Prevalence Monitoring Project: <http://www.cdc.gov/std/chlamydia2007/>
- 2007 Gonococcal Isolate Surveillance Project: <http://www.cdc.gov/std/GISP2007/>
- 2007 Syphilis Surveillance Project: <http://www.cdc.gov/std/Syphilis2007/>

STD Surveillance Reports 1993–2007

- <http://www.cdc.gov/std/stats/>

STD Data on Wonder

- <http://wonder.cdc.gov/std.html>

STD Data Management & Information Technology

- <http://www.cdc.gov/std/Program/data-mgmt.htm>

STD Fact Sheets

- http://www.cdc.gov/std/healthcomm/fact_sheets.htm

STD Treatment Guidelines

- <http://www.cdc.gov/STD/treatment/>

STD Program Evaluation Guidelines

- <http://www.cdc.gov/std/program/pupestd.htm>

STD Program Operation Guidelines

- <http://www.cdc.gov/std/program/default.htm>

Recommendations for Public Health Surveillance of Syphilis in the United States

- <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5233a7.htm>

Behavioral Surveillance

- Youth Risk Behavior Surveillance System: <http://www.cdc.gov/HealthyYouth/yrebs/index.htm>
- National Survey of Family Growth: Advance Data 362. Sexual Behavior and Selected Health Measures: Men and Women 15–44 Years of Age, United States, 2002. 56 pp. (PHS) 2003–1250: <http://www.cdc.gov/nchs/products/pubs/pubd/ad/361–370/ad362.htm>

Foreword

“STDs are hidden epidemics of enormous health and economic consequence in the United States. They are hidden because many Americans are reluctant to address sexual health issues in an open way and because of the biologic and social characteristics of these diseases. All Americans have an interest in STD prevention because all communities are impacted by STDs and all individuals directly or indirectly pay for the costs of these diseases. STDs are public health problems that lack easy solutions because they are rooted in human behavior and fundamental societal problems. Indeed, there are many obstacles to effective prevention efforts. The first hurdle will be to confront the reluctance of American society to openly confront issues surrounding sexuality and STDs. Despite the barriers, there are existing individual- and community-based interventions that are effective and can be implemented immediately. That is why a multifaceted approach is necessary to both the individual and community levels.

To successfully prevent STDs, many stakeholders need to redefine their mission, refocus their efforts, modify how they deliver services, and accept new responsibilities. In this process, strong leadership, innovative thinking, partnerships, and adequate resources will be required. The additional investment required to effectively prevent STDs may be considerable, but it is negligible when compared with the likely return on the investment. The process of preventing STDs must be a collaborative one. No one agency, organization, or sector can effectively do it alone; all members of the community must do their part. A successful national initiative to confront and prevent STDs requires widespread public awareness and participation and bold national leadership from the highest levels.”¹

¹Concluding statement from the Institute of Medicine’s Summary Report, *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*, National Academy Press, Washington, DC, 1997, p.43.

Preface

Sexually Transmitted Disease Surveillance, 2007 presents statistics and trends for sexually transmitted diseases (STDs) in the United States through 2007. This annual publication is intended as a reference document for policy makers, program managers, health planners, researchers, and others who are concerned with the public health implications of these diseases. ***The figures and tables in this edition supersede those in earlier publications of these data.***

The surveillance information in this report is based on the following sources of data: (1) case reports from state and local STD programs; (2) the Regional Infertility Prevention Projects, the National Job Training Program, the Corrections STD Prevalence Monitoring Project, the Indian Health Service, and the Men Who Have Sex With Men (MSM) Prevalence Monitoring Project; (3) the Gonococcal Isolate Surveillance Project (GISP); and (4) national surveys implemented by federal and private organizations.

The STD surveillance systems operated by state and local STD control programs, which provide the case report data for chlamydia, gonorrhea, syphilis, and chancroid are the data sources of many of the figures and most of the statistical tables in this publication. These systems are an integral part of program management at all levels of STD prevention and control in the United States. Because of incomplete diagnosis and reporting, the number of STD cases reported to CDC is less than the actual number of cases occurring in the

United States population. Case report data for other STDs are not available because they are not nationally notifiable diseases.

Sexually Transmitted Disease Surveillance, 2007 consists of four parts. The **National Profile** contains figures that provide an overview of STD morbidity in the United States. The accompanying text identifies major findings and trends for selected STDs. The **Special Focus Profiles** contain figures and text describing STDs in selected subgroups and populations that are a focus of national and state prevention efforts. The **Detailed Tables** provide statistical information about STDs at the county, metropolitan statistical area (MSA), regional, state, and national levels. The **Appendix** includes information on interpreting the STD surveillance data used to produce this report, Healthy People 2010 STD objectives, Government Performance and Results Act (GPRA) goals, and STD surveillance case definitions.

Selected figures and tables in this document identify goals that reflect progress towards some of the Healthy People 2010 (HP2010) national health status objectives for STDs.¹ **Appendix** Table A3 displays progress made towards the HP2010 targets for STDs. These targets are used as reference points throughout this edition of *Sexually Transmitted Disease Surveillance 2007*.

Any comments and suggestions that would improve the usefulness of future publications are appreciated and should be sent to Director, Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E-02, Atlanta, Georgia, 30333.

¹ U.S. Department of Health and Human Services. *Healthy People 2010*. 2nd ed. With Understanding and Improving Health and Objectives for Improving Health. 2 vols. Washington, DC: U.S. Government Printing Office, November 2000.

Acknowledgments

Publication of this report would not have been possible without the contributions of the State and Territorial Health Departments and the Sexually Transmitted Disease Control Programs and the Regional Infertility Prevention Projects, which provided surveillance data to the Centers for Disease Control and Prevention.

This report was prepared by the following staff and contractors of the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention:

Office of the Director

Keith Davis
John Douglas
Melinda Flock
Suzanne Haecker
Amy Pulver
Jill Wasserman
Rachel Wynn

Epidemiology and Surveillance Branch

Stuart Berman
Deblina Datta
Kristen Mahle
Lori Newman
Catherine Lindsey Satterwhite
John Su
Hillard Weinstock
Eileen Yee

Statistics and Data Management Branch

Susan Bradley
Jim Braxton
Delicia Carey
Sharon Clanton
Darlene Davis
LaZetta Grier
Samuel Groseclose
Alesia Harvey
Rose Horsley
Kathleen Hutchins
Rob Nelson
Maya Sternberg
Akbar Zaidi

Contents

Foreword	v
Preface	vi
Acknowledgments	viii
Figures in the National Profile	x
Figures in the Special Focus Profiles	xii
Tables in the National Profile	xiv
Geographic Divisions of the United States	xvii
National Overview of Sexually Transmitted Diseases, 2007	1
National Profile	
Introduction	5
Chlamydia	7
Gonorrhea	17
Syphilis	33
Other Sexually Transmitted Diseases	45
Special Focus Profiles	
Introduction	51
STDs in Women and Infants	53
STDs in Adolescents and Young Adults	63
STDs in Racial and Ethnic Minorities	69
STDs in Men Who Have Sex with Men	79
STDs in Persons Entering Corrections Facilities	87
Tables	
National Summary	99
Chlamydia	101
Gonorrhea	112
Syphilis	124
Chancroid	145
Selected STDs	146
Appendix	
Interpreting STD Surveillance Data	147
Table A1. Selected STDs — Percentage of unknown, missing, or invalid values for selected demographic variables by state, 2007	155
Table A2. Reported cases of sexually transmitted disease by sex and reporting source: United States, 2007	156
Table A3. Healthy People 2010 Sexually Transmitted Diseases Objective Status	157
Table A4. Government Performance Results Act (GPRA) Sexually Transmitted Diseases Goals and Measures	158
STD Surveillance Case Definitions	159
Contributors	168

Figures in the National Profile

Chlamydia

Figure 1.	Chlamydia — Rates: Total and by sex: United States, 1988–2007	11
Figure 2.	Chlamydia — Rates by region: United States, 1998–2007	11
Figure 3.	Chlamydia — Rates by state: United States and outlying areas, 2007	12
Figure 4.	Chlamydia — Rates by county: United States, 2007	12
Figure 5.	Chlamydia — Age- and sex-specific rates: United States, 2007	13
Figure 6.	Chlamydia — Rates by race/ethnicity: United States, 1998–2007	13
Figure 7.	Chlamydia — Cases by reporting source and sex: United States, 1998–2007	14
Figure 8.	Chlamydia — Prevalence by age group and race/ethnicity reported from a national survey, 1999–2002	14
Figure 9.	Chlamydia — Median state-specific positivity among 15- to 24-year-old women tested in family planning clinics: United States, 1997–2007	15
Figure 10.	Chlamydia — Positivity among 15- to 24-year-old women tested in family planning clinics by state: United States and outlying areas, 2007	15
Figure 11.	Chlamydia — Trends in positivity among 15- to 24-year-old women tested in family planning clinics by HHS region, 2003–2007	16
Figure 12.	Chlamydia — Percent of nucleic acid amplification tests (NAATs) used in family planning clinics among 15- to 24-year-old women by HHS region, 2003–2007	16

Gonorrhea

Figure 13.	Gonorrhea — Rates: United States, 1941–2007 and the Healthy People 2010 target	24
Figure 14.	Gonorrhea — Rates: Total and by sex: United States, 1988–2007 and the Healthy People 2010 target	24
Figure 15.	Gonorrhea — Rates by region: United States, 1998–2007 and the Healthy People 2010 target	25
Figure 16.	Gonorrhea — Rates by state: United States and outlying areas, 2007	25
Figure 17.	Gonorrhea — Rates by county: United States, 2007	26
Figure 18.	Gonorrhea — Age- and sex-specific rates: United States, 2007	26
Figure 19.	Gonorrhea — Age-specific rates among women 15 to 44 years of age: United States, 1998–2007	27
Figure 20.	Gonorrhea — Age-specific rates among men 15 to 44 years of age: United States, 1998–2007	27
Figure 21.	Gonorrhea — Rates by race/ethnicity: United States, 1998–2007	28
Figure 22.	Gonorrhea — Cases by reporting source and sex: United States, 1998–2007	28
Figure 23.	Gonorrhea — Positivity among 15- to 24-year-old women tested in family planning clinics by state: United States and outlying areas, 2007	29
Figure 24.	Gonococcal Isolate Surveillance Project (GISP) — Prevalence of ciprofloxacin resistant <i>Neisseria gonorrhoeae</i> by GISP site, 2004–2007	29
Figure 25.	Gonococcal Isolate Surveillance Project (GISP) — Penicillin, tetracycline, and ciprofloxacin resistance among GISP isolates, 2007	30

Figure 26. Gonococcal Isolate Surveillance Project (GISP) — Percent of <i>Neisseria gonorrhoeae</i> isolates with resistance or intermediate resistance to ciprofloxacin, 1990–2007.	30
Figure 27. Gonococcal Isolate Surveillance Project (GISP) — Percent of <i>Neisseria gonorrhoeae</i> isolates with resistance to ciprofloxacin by sexual behavior, 2001–2007	31

Syphilis

Figure 28. Syphilis — Reported cases by stage of infection: United States, 1941–2007.	37
Figure 29. Primary and secondary syphilis — Rates: Total and by sex: United States, 1988–2007 and the Healthy People 2010 target	37
Figure 30. Primary and secondary syphilis — Rates by region: United States, 1998–2007 and the Healthy People 2010 target	38
Figure 31. Primary and secondary syphilis — Rates by state: United States and outlying areas, 2007	38
Figure 32. Primary and secondary syphilis — Rates by county: United States, 2007.	39
Figure 33. Primary and secondary syphilis — Age- and sex-specific rates: United States, 2007	39
Figure 34. Primary and secondary syphilis — Age-specific rates among women 15 to 44 years of age: United States, 1998–2007	40
Figure 35. Primary and secondary syphilis — Age-specific rates among men 15 to 44 years of age: United States, 1998–2007	40
Figure 36. Primary and secondary syphilis — Rates by race/ethnicity: United States, 1998–2007	41
Figure 37. Primary and secondary syphilis — Reported cases by stage and sexual orientation, 2007	41
Figure 38. Primary and secondary syphilis — Reported cases by sexual orientation and race/ethnicity, 2007.	42
Figure 39. Primary and secondary syphilis — Reported cases by reporting source and sex: United States, 1998–2007	42
Figure 40. Primary and secondary syphilis — Percentage of reported cases by sexual orientation and selected reporting sources, 2007.	43
Figure 41. Congenital syphilis (CS) — Reported cases for infants < 1 year of age and rates of primary and secondary syphilis among women: United States, 1998–2007	43

Other Sexually Transmitted Diseases

Figure 42. Chancroid — Reported cases: United States, 1981–2007.	48
Figure 43. Human papillomavirus (HPV) — Prevalence of high-risk and low-risk types among females 14 to 59 years of age reported from a national survey, 2003–2004	48
Figure 44. Genital warts — Initial visits to physicians’ offices: United States, 1966–2007	49
Figure 45. Genital herpes — Initial visits to physicians’ offices: United States, 1966–2007	49
Figure 46. Genital herpes — Herpes simplex virus, type 2, seroprevalence in non-Hispanic whites and non-Hispanic blacks by age group reported from a national survey, 1976–1980, 1988–1994, 1999–2004	50
Figure 47. Trichomoniasis and other vaginal infections in women — Initial visits to physicians’ offices: United States, 1966–2007	51

Figures in the Special Focus Profiles

STDs in Women and Infants

Figure A. Chlamydia — Rates among women by state: United States and outlying areas, 2007.	59
Figure B. Chlamydia — Positivity in 15- to 24-year-old women tested in prenatal clinics by state: United States and outlying areas, 2007	59
Figure C. Gonorrhea — Rates among women by state: United States and outlying areas, 2007.	60
Figure D. Gonorrhea — Positivity in 15- to 24-year-old women tested in prenatal clinics by state: United States and outlying areas, 2007	60
Figure E. Primary and secondary syphilis — Rates among women by state: United States and outlying areas, 2007	61
Figure F. Congenital syphilis — Rates for infants < 1 year of age by state: United States and outlying areas, 2007	61
Figure G. Ectopic pregnancy — Hospitalizations of women 15 to 44 years of age: United States, 1997–2006	62
Figure H. Pelvic inflammatory disease — Hospitalizations of women 15 to 44 years of age: United States, 1997–2006	62
Figure I. Pelvic inflammatory disease — Initial visits to physicians' offices by women 15 to 44 years of age: United States, 1998–2007	63

STDs in Adolescents and Young Adults

Figure J. Chlamydia — Trends in positivity among 15- to 19-year-old women tested in family planning clinics by HHS region, 2003–2007	68
Figure K. Chlamydia — Prevalence among 16- to 24-year-old women entering the National Job Training Program by state of residence: United States and outlying areas, 2007	68
Figure L. Chlamydia — Prevalence among 16- to 24-year-old men entering the National Job Training Program by state of residence: United States and outlying areas, 2007	69
Figure M. Gonorrhea — Prevalence among 16- to 24-year-old women entering the National Job Training Program by state of residence: United States and outlying areas, 2007.	69
Figure N. Gonorrhea — Prevalence among 16- to 24-year-old men entering the National Job Training Program by state of residence: United States and outlying areas, 2007	70

STDs in Racial and Ethnic Minorities

Figure O. Chlamydia — Rates by race/ethnicity and sex: United States, 2007	75
Figure P. Chlamydia — Positivity among 15- to 24-year-old women screened in Indian Health Service (IHS) clinics by HHS region, 2007.	75
Figure Q. Gonorrhea — Rate ratios by race/ethnicity: United States, 1998–2007	76
Figure R. Gonorrhea — Rates by race/ethnicity and sex: United States, 2007	76
Figure S. Gonorrhea — Rate ratios by race/ethnicity and region: United States, 2007	77
Figure T. Primary and secondary syphilis — Rates by race/ethnicity and sex: United States, 2007	77

Figure U. Primary and secondary syphilis — Rates among 15- to 19-year-old females by race/ethnicity: United States, 1998–2007	78
Figure V. Primary and secondary syphilis — Rates among 15- to 19-year-old males by race/ethnicity: United States, 1998–2007	78
Figure W. Congenital syphilis — Rates among infants < 1 year of age by mother’s race/ethnicity: United States, 1998–2007	79

STDs in Men Who Have Sex with Men

Figure X. MSM Prevalence Monitoring Project — Number of gonorrhea tests and number of positive tests in men who have sex with men, STD clinics, 1999–2007	85
Figure Y. MSM Prevalence Monitoring Project — Syphilis serologic reactivity among men who have sex with men, STD clinics, 1999–2007	85
Figure Z. MSM Prevalence Monitoring Project — City-specific median number of HIV tests and positivity among men who have sex with men, STD clinics, 1999–2007	87
Figure AA. MSM Prevalence Monitoring Project — Test positivity for gonorrhea, chlamydia, and HIV and seroreactivity to syphilis among men who have sex with men, by race/ethnicity, STD clinics, 2007	87
Figure BB. Gonococcal Isolate Surveillance Project (GISP) — Percent of urethral <i>Neisseria gonorrhoeae</i> isolates obtained from men who have sex with men attending STD clinics, 1988–2007	88
Figure CC. Gonococcal Isolate Surveillance Project (GISP) — Percent of urethral <i>Neisseria gonorrhoeae</i> isolates obtained from men who have sex with men attending STD clinics by GISP site, 2004–2007	88

STDs in Persons Entering Corrections Facilities

Figure DD. Chlamydia — Positivity by age and sex, juvenile corrections facilities, 2007	92
Figure EE. Chlamydia — Positivity by age group and sex, adult corrections facilities, 2007	92
Figure FF. Gonorrhea — Positivity by age and sex, juvenile corrections facilities, 2007	93
Figure GG. Gonorrhea — Positivity by age group and sex, adult corrections facilities, 2007	93

Tables in the National Profile

National Summary

Table 1.	Cases of sexually transmitted diseases reported by state health departments and rates per 100,000 population: United States, 1941–2007	99
----------	--	----

Chlamydia

Table 2.	Chlamydia — Reported cases and rates by state, ranked by rates: United States, 2007	101
Table 3.	Chlamydia — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007. . .	102
Table 4.	Chlamydia — Women – Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	103
Table 5.	Chlamydia — Men – Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	104
Table 6.	Chlamydia — Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	105
Table 7.	Chlamydia — Women – Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	106
Table 8.	Chlamydia — Men – Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	107
Table 9.	Chlamydia — Counties and independent cities ranked by number of reported cases: United States, 2007	108
Table 10.	Chlamydia — Reported cases and rates per 100,000 population by age group and sex: United States, 2003–2007	109
Table 11A.	Chlamydia — Reported cases by race/ethnicity, age group and sex: United States, 2003–2007	110
Table 11B.	Chlamydia — Rates per 100,000 population by race/ethnicity, age group and sex: United States, 2003–2007	111

Gonorrhea

Table 12.	Gonorrhea — Reported cases and rates by state, ranked by rates: United States, 2007.	112
Table 13.	Gonorrhea — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007 . . .	113
Table 14.	Gonorrhea — Women – Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	114
Table 15.	Gonorrhea — Men – Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	115

Table 16.	Gonorrhea — Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	116
Table 17.	Gonorrhea — Women – Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	117
Table 18.	Gonorrhea — Men – Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	118
Table 19.	Gonorrhea — Counties and independent cities ranked by number of reported cases: United States, 2007	119
Table 20.	Gonorrhea — Reported cases and rates per 100,000 population by age group and sex: United States, 2003–2007	120
Table 21A.	Gonorrhea — Reported cases by race/ethnicity, age group and sex: United States, 2003–2007	122
Table 21B.	Gonorrhea — Rates per 100,000 population by race/ethnicity, age group and sex: United States, 2003–2007	123

Syphilis

Table 22.	All stages of syphilis — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	124
Table 23.	All stages of syphilis — Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	125
Table 24.	Primary and secondary syphilis — Reported cases and rates by state, ranked by rates: United States, 2007	126
Table 25.	Primary and secondary syphilis — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	127
Table 26.	Primary and secondary syphilis — Women – Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	128
Table 27.	Primary and secondary syphilis — Men – Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	129
Table 28.	Primary and secondary syphilis — Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	130
Table 29.	Primary and secondary syphilis — Women – Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	131
Table 30.	Primary and secondary syphilis — Men – Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	132
Table 31.	Primary and secondary syphilis — Counties and independent cities ranked by number of reported cases: United States, 2007	133
Table 32.	Primary and secondary syphilis — Reported cases and rates per 100,000 population by age group and sex: United States, 2003–2007	134
Table 33A.	Primary and secondary syphilis — Reported cases by race/ethnicity, age group and sex: United States, 2003–2007	136

Table 33B.	Primary and secondary syphilis — Rates per 100,000 population by race/ethnicity, age group and sex: United States, 2003–2007	137
Table 34.	Early latent syphilis — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	138
Table 35.	Early latent syphilis — Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	139
Table 36.	Late and late latent syphilis — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	140
Table 37.	Late and late latent syphilis — Reported cases and rates in selected metropolitan statistical areas (MSAs) listed in alphabetical order: United States, 2003–2007	137
Table 38.	Congenital syphilis — Reported cases and rates in infants < 1 year of age by state, ranked by rates: United States, 2007	142
Table 39.	Congenital syphilis — Reported cases and rates in infants < 1 year of age by state/area and region listed in alphabetical order: United States and outlying areas, 2003–2007	143
Table 40.	Congenital syphilis — Reported cases and rates in infants < 1 year of age by race/ethnicity of mother: United States, 2003–2007	144

Chancroid

Table 41.	Chancroid — Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 2003–2007	145
-----------	--	-----


Selected STDs

Table 42.	Selected STDs and complications — Initial visits to physicians' offices, National Disease and Therapeutic Index: United States, 1966–2007	146
-----------	---	-----

Interpreting STD Surveillance Data

Table A1.	Selected STDs — Percentage of unknown, missing, or invalid values for selected variables by state and by nationally notifiable STD, 2007	155
Table A2.	Reported cases of sexually transmitted disease by reporting source and sex: United States, 2007	156
Table A3.	Healthy People 2010 Sexually Transmitted Diseases Objective Status	157
Table A4.	Government Performance Results Act (GPRA) Sexually Transmitted Diseases Goals and Measures.	158

Geographic Divisions of the United States



West

Alaska
 Arizona
 California
 Colorado
 Hawaii
 Idaho
 Montana
 Nevada
 New Mexico
 Oregon
 Utah
 Washington
 Wyoming

Midwest

Illinois
 Indiana
 Iowa
 Kansas
 Michigan
 Minnesota
 Missouri
 Nebraska
 North Dakota
 Ohio
 South Dakota
 Wisconsin

South

Alabama
 Arkansas
 Delaware
 District of Columbia
 Florida
 Georgia
 Kentucky
 Louisiana
 Maryland
 Mississippi
 North Carolina
 Oklahoma
 South Carolina
 Tennessee
 Texas
 Virginia
 West Virginia

Northeast

Connecticut
 Maine
 Massachusetts
 New Hampshire
 New Jersey
 New York
 Pennsylvania
 Rhode Island
 Vermont

National Overview of Sexually Transmitted Diseases, 2007

The logo on the cover of *Sexually Transmitted Disease Surveillance, 2007* is a reminder of the multifaceted, national dimensions of the morbidity, mortality, and costs that result from sexually transmitted diseases (STDs) in the United States. It highlights the central role of STD prevention in improving health among women and infants and in promoting HIV prevention. Organized collaboration among interested, committed public and private organizations and communities is the key to reducing STDs and their related health burdens. As noted in the report of the Institute of Medicine, *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*,¹ surveillance is a key component of our efforts to prevent and control these diseases.

This overview summarizes national surveillance data on the three notifiable diseases for which there are federally-funded control programs: chlamydia, gonorrhea, and syphilis. Several observations for 2007 are worthy of note.

Chlamydia

In 2007, 1,108,374 cases of sexually transmitted *Chlamydia trachomatis* infection were reported to CDC (Table 1). This is the largest number of cases ever reported to CDC for any condition. This case count corresponds to a rate of 370.2 cases per 100,000 population, an increase of 7.5% compared with the rate in 2006. Rates of reported chlamydial infections among women have been increasing annually since the late 1980s when public

programs for screening and treatment of women were first established to avert pelvic inflammatory disease and related complications. The continued increase in chlamydia case reports in 2007 most likely represents a continued increase in screening for this infection, more sensitive tests, and more complete national reporting, but it may also reflect a true increase in morbidity.

In 2007, the overall rate of chlamydial infection in the United States among women (543.6 cases per 100,000 females) was almost three times the rate among men (190.0 cases per 100,000 males), reflecting the large number of women screened for this disease (Tables 4 and 5). However, with the increased availability of urine testing, men are increasingly being tested for chlamydial infection. From 2003 through 2007, the chlamydia rate in men increased by 43% (compared with a 17% increase in women over this period).

Data from multiple sources on prevalence of chlamydial infection in defined populations have been useful in monitoring disease burden and guiding chlamydia screening programs.

In 2007, the median state-specific chlamydia test positivity among women 15 to 24 years of age who were screened at selected family planning clinics in all states, the District of Columbia, Puerto Rico, and the Virgin Islands was 6.9% (range: 2.9% to 16.8%) (Figures 9 and 10).

At selected prenatal clinics in 22 states, Puerto Rico, and the Virgin Islands the median state-specific chlamydia prevalence was 7.4% (range: 2.0% to 20.7%) (Figure B).

The prevalence of infection is greater among economically-disadvantaged women 16 to 24 years of age who entered the National Job Training Program in 2007 from 40 states, the District of Columbia, and Puerto Rico. The median state-specific prevalence was 13.2% (range: 3.8% to 23.5%) (Figure K). Among men entering the program in 2007 from 47 states, the District of Columbia, and Puerto Rico the median state-specific chlamydia prevalence was 7.2% (range: 2.0% to 14.5%) (Figure L).

The prevalence is also high among adolescent women entering juvenile detention centers. In 73 centers the median chlamydia positivity by facility was 14.3% (range: 2.5% to 32.1%) (Table A).

Among adolescent men entering 109 juvenile detention centers, the median chlamydia positivity by facility was 5.7% (range: 0.0% to 14.2%) (Table A).

Although these data on prevalence are not entirely comparable because of differences in the populations screened, in the performance characteristics of the screening tests, and variations in screening criteria, they provide important information on the continuing high burden of disease in the United States.

Gonorrhea

Following a 74% decline in the rate of reported gonorrhea from 1975 to 1997, overall gonorrhea rates appeared to plateau. In 2007, 355,991 cases of gonorrhea were reported in the United States, corresponding to a rate of 118.9 cases per 100,000 population, little change from the rate in 2006 of 119.7 cases (Figure 13 and Table 1). This rate considerably exceeds the Healthy People

2010 (HP2010) target of 19 cases per 100,000 population.

As in previous years, in 2007 the South had the highest gonorrhea rate among the four regions of the country (Table 13). Although the gonorrhea rate in the South declined for many years, it increased by 5.3% between 2003 and 2006. In 2007, the rate remained essentially unchanged from 2006. The rate in the West decreased slightly in 2007 after a 29% increase between 2003 and 2006. While rates increased slightly in the Northeast and Midwest from 2006 to 2007, they have remained relatively stable over the past five years.

For the sixth consecutive year, the gonorrhea rate in women in 2007 was higher (123.5 per 100,000 population) than the rate among men (113.7 per 100,000 population) (Figure 14). As with chlamydia, gonorrhea rates in women 15 to 24 years of age are particularly high. In men, they are highest among men 20 to 29 years of age (Figure 18). In 2007, the gonorrhea rate among black men was 26 times higher than that in white men; the gonorrhea rate for black women was 15 times higher than that in white women.

In 2007, data on gonorrhea prevalence in defined populations were available from several sources. These data showed a continuing high burden of disease in adolescents and young adults in parts of the United States.

For 16- to 24-year-old women entering the National Job Training Program in 36 states, and Puerto Rico in 2007, the median state-specific gonorrhea prevalence was 3.0% (range: 0.0% to 7.2%) (Figure M).

Among men entering the program from 32 states and Puerto Rico, the median state-specific gonorrhea prevalence was 1.1% (range: 0.0% to 4.4%) (Figure N).

Among women entering juvenile corrections facilities the median gonorrhea

positivity was 5.3% (range: 0.0% to 13.9%); the median gonorrhea positivity for men entering juvenile corrections facilities was 1.0% (range: 0.0% to 4.5%).

Among men who have sex with men (MSM) attending eight STD clinics, the median clinic urethral gonorrhea positivity was 8.0% (range: 5% to 15%).

In the Gonococcal Isolate Surveillance Project (GISP), a sentinel surveillance project in 30 STD clinics throughout the United States, 36% of the isolates from MSM were resistant to ciprofloxacin in 2007. The overall proportion of resistant isolates among heterosexuals was 8.7%. As a result of the high prevalence of quinolone resistant *N. gonorrhoeae* among MSM and heterosexuals, CDC revised the STD Treatment Guidelines in 2007. Fluoroquinolones are no longer recommended for the treatment of gonorrhea and associated conditions such as pelvic inflammatory disease.²

Syphilis

The rate of primary and secondary (P&S) syphilis reported in the United States decreased during the 1990s and in 2000 was the lowest since reporting began in 1941. The low rate of syphilis and the concentration of the majority of syphilis cases in a small number of geographic areas led to the development of the National Plan to Eliminate Syphilis, which was announced by the Surgeon General in 1999 and updated in 2006.³ The rate of P&S syphilis in the United States declined by 89.7% from 1990 through 2000. However, the rate of P&S syphilis has increased each year since 2001, mostly in men, but also in women for the past three years. In 2007, 11,466 cases of P&S syphilis were reported to CDC, corresponding to a rate of 3.8 cases per 100,000 population, a 15% increase from 2006. Since 2001, the rate of P&S syphilis has increased 81%. After 14 years of

decline, the rate of congenital syphilis increased in 2006 and again in 2007, a 28% increase since 2005. There were 430 cases of congenital syphilis reported in 2007 compared to 382 reported cases in 2006 and 339 in 2005.

Although wide disparities exist in the rates of STDs among racial and ethnic groups, there has been a reduction in these differences for syphilis over the past eight years. The P&S syphilis rate for 2007 in blacks was 7 times the rate in whites, which is substantially lower than the disparity observed in 1999, when the rate among blacks was 29 times greater than that among whites (Table 33B). However, with increases in syphilis among blacks occurring since 2003 at a greater rate than those among whites, we are no longer seeing declines in this health disparity. In 2007, increases were observed among both black men (23.2 cases per 100,000 population, up from 18.1 in 2006) and black women (5.6 cases per 100,000 population, up from 4.9 in 2006). Smaller increases were observed among white men (3.7 cases per 100,000 population, up from 3.5 in 2006) and white women (0.4 per 100,000 population, up from 0.3 per 100,000 in 2006).

While syphilis elimination efforts have successfully focused on heterosexual minority populations at risk for syphilis, increases in syphilis among MSM since 2001 and more recent increases among women and blacks highlight the importance of continually reassessing and refining surveillance, prevention, and control strategies.

¹ Institute of Medicine. *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*, Committee on Prevention and Control of Sexually Transmitted Diseases, National Academy Press, Washington, DC, 1997.

² Centers for Disease Control and Prevention. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections. *MMWR*, 2007;56:332-336.

³ Division of STD Prevention. *The National Plan to Eliminate Syphilis from the United States*. National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 2006